Compare Illumina, Inc. (ILMN) vs Microsoft (MSFT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Microsoft — how do they compare? Illumina, Inc. trades at $191.43 (market cap $27.94B), while Microsoft trades at $398.61 (market cap $2.99T). The key difference: Microsoft is far larger — about 107× Illumina, Inc.'s market cap, and Microsoft pays a 0.9% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | MSFT | |
|---|---|---|
Market Cap | $27.94B | $2.99T |
Sector | Health | Technology |
52-Week High | $194.33 | $542.07 |
52-Week Low | $91.00 | $352.83 |
Enterprise Value | $29.33B | $2.97T |
Volume | — | 36,654,621 |
Dividend Yield | — | 0.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
Microsoft (MSFT) trades at $399.48, up 1.44% today, with strong technical momentum as the stock approaches resistance at $407. The company demonstrates robust fundamentals with Q1 2026 EPS beating expectations at $4.27 versus $4.06, continuing a trend of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $281.72 billion and net income of $101.83 billion, supported by strong cash flow generation of $136.16 billion from operations.
Microsoft's outlook remains positive with 80% analyst buy ratings and a $546.70 consensus price target representing 37% upside potential. Key opportunities include AI leadership through Azure and Copilot, while risks include elevated capital expenditures and competitive pressures in cloud computing. The stock's current valuation at 23.96 P/E appears reasonable given growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →
